{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:59:27Z","timestamp":1792483167657,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007465","name":"UiT The Arctic University of Norway","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007465","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00198-025-07697-6","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T21:43:33Z","timestamp":1758750213000},"page":"2263-2272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adherence to secondary fracture prevention is associated with reduced risk of subsequent fractures"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3123-2950","authenticated-orcid":false,"given":"\u00c5shild","family":"Bj\u00f8rnerem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jashar","family":"Khoshkhabari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Kristin","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tove Tveitan","family":"Borgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frede","family":"Frihagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene Bergendal","family":"Solberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tone Kristin","family":"Omsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frida Igland","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"issue":"8","key":"7697_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10654-009-9353-8","volume":"24","author":"LA Ahmed","year":"2009","unstructured":"Ahmed LA, Schirmer H, Bjornerem A, Emaus N, Jorgensen L, Stormer J et al (2009) The gender- and age-specific 10-year and lifetime absolute fracture risk in Tromso. Norway Eur J Epidemiol 24(8):441\u2013448","journal-title":"Norway Eur J Epidemiol"},{"key":"7697_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.bone.2014.02.016","volume":"63","author":"TK Omsland","year":"2014","unstructured":"Omsland TK, Emaus N, Tell GS, Magnus JH, Ahmed LA, Holvik K et al (2014) Mortality following the first hip fracture in Norwegian women and men (1999\u20132008). A NOREPOS study. Bone 63:81\u201386","journal-title":"Bone"},{"issue":"3","key":"7697_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00223-015-0089-z","volume":"98","author":"FJ Lotters","year":"2016","unstructured":"Lotters FJ, van den Bergh JP, de Vries F, Rutten-van Molken MP (2016) Current and future incidence and costs of osteoporosis-related fractures in the Netherlands: combining claims data with BMD measurements. Calcif Tissue Int 98(3):235\u2013243","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"7697_CR4","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s00198-024-07059-8","volume":"35","author":"M Chandran","year":"2024","unstructured":"Chandran M, Akesson KE, Javaid MK, Harvey N, Blank RD, Brandi ML et al (2024) Impact of osteoporosis and osteoporosis medications on fracture healing: a narrative review. Osteoporos Int 35(8):1337\u20131358","journal-title":"Osteoporos Int"},{"issue":"10","key":"7697_CR5","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s10654-012-9711-9","volume":"27","author":"TK Omsland","year":"2012","unstructured":"Omsland TK, Holvik K, Meyer HE, Center JR, Emaus N, Tell GS et al (2012) Hip fractures in Norway 1999\u20132008: time trends in total incidence and second hip fracture rates. A NOREPOS study. Eur J Epidemiol 27(10):807\u2013814","journal-title":"Eur J Epidemiol"},{"issue":"18","key":"7697_CR6","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799\u20131809","journal-title":"N Engl J Med"},{"issue":"10","key":"7697_CR7","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S et al (2014) Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 25(10):2359\u20132381","journal-title":"Osteoporos Int"},{"key":"7697_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bone.2018.07.013","volume":"116","author":"BL Langdahl","year":"2018","unstructured":"Langdahl BL, Silverman S, Fujiwara S, Saag K, Napoli N, Soen S et al (2018) Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: integrated analysis of 4 prospective observational studies. Bone 116:58\u201366","journal-title":"Bone"},{"issue":"7","key":"7697_CR9","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00198-024-07049-w","volume":"35","author":"J Lane","year":"2024","unstructured":"Lane J, Langdahl B, Stone M, Kurth A, Oates M, Timoshanko J et al (2024) Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials. Osteoporos Int 35(7):1195\u20131204","journal-title":"Osteoporos Int"},{"key":"7697_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guanabens N et al (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317","journal-title":"Bone"},{"issue":"4","key":"7697_CR11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/BOR.0000000000000401","volume":"29","author":"K Briot","year":"2017","unstructured":"Briot K (2017) Fracture liaison services. Curr Opin Rheumatol 29(4):416\u2013421","journal-title":"Curr Opin Rheumatol"},{"issue":"8","key":"7697_CR12","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s00198-021-05911-9","volume":"32","author":"N Li","year":"2021","unstructured":"Li N, Hiligsmann M, Boonen A, van Oostwaard MM, de Bot R, Wyers CE et al (2021) The impact of fracture liaison services on subsequent fractures and mortality: a systematic literature review and meta-analysis. Osteoporos Int 32(8):1517\u20131530","journal-title":"Osteoporos Int"},{"issue":"4","key":"7697_CR13","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.2106\/JBJS.L.00223","volume":"96","author":"KM Huntjens","year":"2014","unstructured":"Huntjens KM, van Geel TA, van den Bergh JP, van Helden S, Willems P, Winkens B et al (2014) Fracture liaison service: impact on subsequent nonvertebral fracture incidence and mortality. J Bone Joint Surg Am 96(4):e29","journal-title":"J Bone Joint Surg Am"},{"issue":"3","key":"7697_CR14","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00198-015-3443-0","volume":"27","author":"A Nakayama","year":"2016","unstructured":"Nakayama A, Major G, Holliday E, Attia J, Bogduk N (2016) Evidence of effectiveness of a fracture liaison service to reduce the re-fracture rate. Osteoporos Int 27(3):873\u2013879","journal-title":"Osteoporos Int"},{"issue":"11","key":"7697_CR15","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1007\/s00198-016-3643-2","volume":"27","author":"KF Axelsson","year":"2016","unstructured":"Axelsson KF, Jacobsson R, Lund D, Lorentzon M (2016) Effectiveness of a minimal resource fracture liaison service. Osteoporos Int 27(11):3165\u20133175","journal-title":"Osteoporos Int"},{"issue":"2","key":"7697_CR16","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/ageing\/afv204","volume":"45","author":"S Hawley","year":"2016","unstructured":"Hawley S, Javaid MK, Prieto-Alhambra D, Lippett J, Sheard S, Arden NK et al (2016) Clinical effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients: population-based longitudinal study. Age Ageing 45(2):236\u2013242","journal-title":"Age Ageing"},{"issue":"7","key":"7697_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1759720X17706464","volume":"9","author":"IJA de Bruin","year":"2017","unstructured":"de Bruin IJA, Wyers CE, van den Bergh JPW, Geusens P (2017) Fracture liaison services: do they reduce fracture rates? Ther Adv Musculoskelet Dis 9(7):157\u2013164","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"6","key":"7697_CR18","doi-asserted-by":"publisher","first-page":"e0198006","DOI":"10.1371\/journal.pone.0198006","volume":"13","author":"T van Geel","year":"2018","unstructured":"van Geel T, Bliuc D, Geusens PPM, Center JR, Dinant GJ, Tran T et al (2018) Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation in a fracture liaison service setting: A prospective cohort study. PLoS ONE 13(6):e0198006","journal-title":"PLoS ONE"},{"issue":"7","key":"7697_CR19","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/jbmr.3990","volume":"35","author":"KF Axelsson","year":"2020","unstructured":"Axelsson KF, Johansson H, Lundh D, Moller M, Lorentzon M (2020) Association between recurrent fracture risk and implementation of fracture liaison services in four Swedish hospitals: a cohort study. J Bone Miner Res 35(7):1216\u20131223","journal-title":"J Bone Miner Res"},{"issue":"8","key":"7697_CR20","doi-asserted-by":"publisher","first-page":"e185701","DOI":"10.1001\/jamanetworkopen.2018.5701","volume":"1","author":"C Andreasen","year":"2018","unstructured":"Andreasen C, Solberg LB, Basso T, Borgen TT, Dahl C, Wisloff T et al (2018) Effect of a fracture liaison service on the rate of subsequent fracture among patients with a fragility fracture in the Norwegian capture the fracture initiative (NoFRACT): a trial protocol. JAMA Netw Open 1(8):e185701","journal-title":"JAMA Netw Open"},{"issue":"3","key":"7697_CR21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00198-024-07376-y","volume":"36","author":"C Andreasen","year":"2025","unstructured":"Andreasen C, Dahl C, Frihagen F, Borgen TT, Basso T, Gjertsen JE et al (2025) Fracture liaison service (FLS) is associated with lower subsequent fragility fracture risk and mortality: NoFRACT (the Norwegian capture the fracture initiative). Osteoporos Int 36(3):501\u2013512","journal-title":"Osteoporos Int"},{"issue":"5","key":"7697_CR22","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00198-017-4370-z","volume":"29","author":"CH Wu","year":"2018","unstructured":"Wu CH, Chen CH, Chen PH, Yang JJ, Chang PC, Huang TC et al (2018) Identifying characteristics of an effective fracture liaison service: systematic literature review. Osteoporos Int 29(5):1023\u20131047","journal-title":"Osteoporos Int"},{"issue":"1","key":"7697_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30(1):3\u201344","journal-title":"Osteoporos Int"},{"issue":"1","key":"7697_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-015-0235-2","volume":"10","author":"M Hoff","year":"2015","unstructured":"Hoff M, Skurtveit S, Meyer HE, Langhammer A, S\u00f8gaard AJ, Syversen U et al (2015) Use of anti-osteoporotic drugs in central Norway after a forearm fracture. Arch Osteoporos 10(1):30","journal-title":"Arch Osteoporos"},{"issue":"4","key":"7697_CR25","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s00198-012-2063-1","volume":"24","author":"H Devold","year":"2013","unstructured":"Devold H, S\u00f8gaard A, Tverdal A, Falch J, Furu K, Meyer H (2013) Hip fracture and other predictors of anti-osteoporosis drug use in Norway. Osteoporos Int 24(4):1225\u20131233","journal-title":"Osteoporos Int"},{"issue":"11","key":"7697_CR26","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00198-019-05104-5","volume":"30","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Cornelissen D, Vrijens B, Abrahamsen B, Al-Daghri N, Biver E et al (2019) Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). Osteoporos Int 30(11):2155\u20132165","journal-title":"Osteoporos Int"},{"issue":"1","key":"7697_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010014","volume":"12","author":"GRA Mangano","year":"2022","unstructured":"Mangano GRA, Avola M, Blatti C, Caldaci A, Sapienza M, Chiaramonte R et al (2022) Non-adherence to anti-osteoporosis medication: factors influencing and strategies to overcome it. A narrative review. J Clin Med 12(1):14","journal-title":"J Clin Med"},{"issue":"1","key":"7697_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00198-010-1274-6","volume":"22","author":"SL Silverman","year":"2011","unstructured":"Silverman SL, Schousboe JT, Gold DT (2011) Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int 22(1):21\u201326","journal-title":"Osteoporos Int"},{"issue":"10","key":"7697_CR29","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","volume":"164","author":"ES Siris","year":"2004","unstructured":"Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE et al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164(10):1108\u20131112","journal-title":"Arch Intern Med"},{"issue":"8","key":"7697_CR30","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJMoa1916525","volume":"383","author":"DM Black","year":"2020","unstructured":"Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH, Ryan DS et al (2020) Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med 383(8):743\u2013753","journal-title":"N Engl J Med"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07697-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07697-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07697-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T12:32:21Z","timestamp":1763382741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07697-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["7697"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07697-6","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u00c5B, JK, AKH, TKO and FIN, no support from any organization for the submitted work; FF reports lecturing fees from UCB and Amgen; TTB reports speaker fees from UCB, Amgen, Roche Diagnostics, and Pharma Prim and participation in an advisory board for UCB, LBS reports speaker fees from Eli Lilly, Amgen and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}